SF3B1 and acute myeloid leukemia: The most common SF3B1 K700E mutation confers a favorable prognosis in MDS cases and is associated with a lower risk of progression to AML compared with patients with wild-type SF3B1 [2,14], whereas a K666N mutation has been found to be associated with a poorer prognosis [19].